Skip to main content
Premium Trial:

Request an Annual Quote

Deltagen Reports Loss, Increased Revenues for Q1

NEW YORK, May 16 - Deltagen, after downsizing the company earlier this year, reported increased revenues for the first quarter yesterday.

 

The company had revenues of $4.6 million for the first quarter, compared to $2.6 million during the same period last year. Its losses in the first quarter totaled $18.0 million, slightly down from $18.7 million a year ago. This includes $9.3 million in restructuring charges related to the downsizing of the company.

 

Deltagen's R&D expenses decreased significantly to $10.1 million, down from $16.8 million for the first quarter of last year.

 

In April, Deltagen secured a bridge loan of $5 million as well as a private placement of $10 million from existing institutional investors.

 

As of March 31, the company had $2.7 million in cash, cash equivalents, and marketable securities, compared to $13.8 million at the end of December, 2002.

 

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.